170 related articles for article (PubMed ID: 11587484)
1. Intestinal first-pass metabolism of eperisone in the rat.
Mihara K; Matsumura M; Yoshioka E; Hanada K; Nakasa H; Ohmori S; Kitada M; Ogata H
Pharm Res; 2001 Aug; 18(8):1131-7. PubMed ID: 11587484
[TBL] [Abstract][Full Text] [Related]
2. Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone.
Yoo HH; Kim NS; Lee J; Sohn DR; Jin C; Kim DH
Xenobiotica; 2009 Jan; 39(1):1-10. PubMed ID: 19219743
[TBL] [Abstract][Full Text] [Related]
3. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.
Lampen A; Christians U; Guengerich FP; Watkins PB; Kolars JC; Bader A; Gonschior AK; Dralle H; Hackbarth I; Sewing KF
Drug Metab Dispos; 1995 Dec; 23(12):1315-24. PubMed ID: 8689938
[TBL] [Abstract][Full Text] [Related]
5. Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats.
Wang X; Zheng M; Liu J; Huang Z; Bai Y; Ren Z; Wang Z; Tian Y; Qiao Z; Liu W; Feng F
J Ethnopharmacol; 2017 Sep; 209():175-183. PubMed ID: 28755970
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
8. Absorption and metabolic extraction of diltiazem from the perfused rat small intestine.
Iwao T; Inoue K; Hayashi Y; Yuasa H; Watanabe J
Drug Metab Pharmacokinet; 2004 Dec; 19(6):430-7. PubMed ID: 15681897
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
[TBL] [Abstract][Full Text] [Related]
10. First-pass metabolism of ONO-5046 (N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino]benzoyl]aminoacetic acid), a novel elastase inhibitor, in rats.
Watanabe F; Sato M; Kato A; Murakami T; Higashi Y; Yata N
Biol Pharm Bull; 1997 Apr; 20(4):392-6. PubMed ID: 9145216
[TBL] [Abstract][Full Text] [Related]
11. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
12. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.
Hashizume T; Imaoka S; Mise M; Terauchi Y; Fujii T; Miyazaki H; Kamataki T; Funae Y
J Pharmacol Exp Ther; 2002 Jan; 300(1):298-304. PubMed ID: 11752129
[TBL] [Abstract][Full Text] [Related]
13. Transdermal eperisone elicits more potent and longer-lasting muscle relaxation than oral eperisone.
Yang SI; Park HY; Lee SH; Lee SJ; Han OY; Lim SC; Jang CG; Lee WS; Shin YH; Kim JJ; Lee SY
Pharmacology; 2004 Jul; 71(3):150-6. PubMed ID: 15161997
[TBL] [Abstract][Full Text] [Related]
14. Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats.
Aiba T; Takehara Y; Okuno M; Hashimoto Y
Pharm Res; 2003 May; 20(5):745-8. PubMed ID: 12751629
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin metabolism by human gastrointestinal mucosal microsomes.
Webber IR; Peters WH; Back DJ
Br J Clin Pharmacol; 1992 Jun; 33(6):661-4. PubMed ID: 1389941
[TBL] [Abstract][Full Text] [Related]
16. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
Perloff MD; Von Moltke LL; Greenblatt DJ
Xenobiotica; 2003 Apr; 33(4):365-77. PubMed ID: 12745872
[TBL] [Abstract][Full Text] [Related]
17. Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism.
Mudra DR; Borchardt RT
J Pharm Sci; 2010 Feb; 99(2):982-98. PubMed ID: 19746412
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats.
Hanada K; Ikemi Y; Kukita K; Mihara K; Ogata H
Drug Metab Dispos; 2008 Oct; 36(10):2037-42. PubMed ID: 18617604
[TBL] [Abstract][Full Text] [Related]
19. Enantioselective carbonyl reduction of eperisone in human liver microsomes.
Yoo HH; Kim NS; Kim MJ; Shin D; Shin JG; Kim DH
Xenobiotica; 2011 Sep; 41(9):758-63. PubMed ID: 21623702
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of intestinal absorption and metabolism of promising anti-Alzheimer's dimer bis(7)-tacrine.
Zhang L; Yu H; Li WM; Cheung MC; Pang YP; Gu ZM; Chan K; Wang YT; Zuo Z; Han YF
Int J Pharm; 2008 Jun; 357(1-2):85-94. PubMed ID: 18358649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
